RESUMEN

BACKGROUND: Herein, we identified miRNA signatures that were able to differentiate malignant prostate cancer from benign prostate hyperplasia and revealed the therapeutic potential of these miRNAs against prostate cancer development. METHODS AND RESULTS: MicroRNA expressions were determined by qPCR. MTT was used for cell viability analysis and immunohistochemistry was performed for Bax/Bcl-2 staining. ELISA was used to measure MMP2/9 levels. Wound healing assay was used for the evaluation of cell migration. Notably, expression levels of miR-125b-5p, miR-145-5p and miR-221-3p were significantly reduced in prostate cancer patients as compared to BPH patients. Moreover, ectopic expression of miR-125b-5p, miR-145-5p and miR-221-3p resulted in significant inhibition of cell proliferation and altered cell morphology. Also, expression level of Bax protein was increased while Bcl-2 level was reduced in cells treated with miR-125b-5p, miR-145-5p and miR-221-3p mimics. Enhanced expression of miR-125b-5p, miR-145-5p and miR-221-3p was also significantly altered the expression of caspase 3 and 8 levels. In addition, MMP9 levels were significantly reduced in cells ectopically expressing miR-221-3p. All miRNA mimics significantly interfered with the migration of prostate cancer cells. CONCLUSIONS: Consequently, our findings point to an important role of these three miRNAs in prostate cancer and indicate that miR-125b-5p, miR-145-5p and miR-221-3p are potential therapeutic targets against prostate cancer.

Asunto(s)

Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , MicroARNs/genética , Neoplasias de la Próstata/genética , Transcriptoma , Anciano , Biomarcadores de Tumor , Línea Celular Tumoral , MicroARN Circulante , Biología Computacional/métodos , Manejo de la Enfermedad , Susceptibilidad a Enfermedades , Ensayo de Inmunoadsorción Enzimática , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Estadificación de Neoplasias , Pronóstico , Neoplasias de la Próstata/diagnóstico , Neoplasias de la Próstata/terapia

RESUMEN

Cyclophosphamide (CP) is a common anticancer drug, but its use in cancer treatment is limited due to its severe toxicities induced mainly by oxidative stress in normal cells. Reactive oxygen species (ROS) lead to multiple organ injuries, including the kidneys. Selenium (Se) is a nutritionally essential trace element with antioxidant properties. In the present study, the possible protective effect of Se on CP-induced acute nephrotoxicity was investigated. Forty-two Sprague-Dawley rats were equally divided into six groups of seven rats in each. The control group received saline, and other groups were injected with CP (150 mg/kg), Se (0.5 or 1 mg/kg), or CP + Se intraperitoneally. Total antioxidant capacity (TAC), total oxidant state (TOS), oxidative stress index (OSI), creatinine, and cystatin C (Cys C) levels were measured in the sera. In addition, kidney tissues were examined histologically. In the CP alone treated rats, creatinine, Cys C, TOS, and OSI levels increased, while TAC level decreased. CP-induced histological damages were decreased by co-treatment of Se and biochemical results supported the microscopic observations. In conclusion, our study points to the therapeutic potential of Se and indicates a significant role of ROS in CP-induced kidney toxicity.

Asunto(s)

Ciclofosfamida/efectos adversos , Riñón/efectos de los fármacos , Riñón/metabolismo , Selenio/farmacología , Animales , Antioxidantes/metabolismo , Masculino , Malondialdehído/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo

RESUMEN

Inhibiting ceramidase activity in cancer cells has been identified as a promising target for cancer therapy in recent studies. uhTs, we examined the possible role of ceranib-2, a novel ceramidase inhibitor, on growth and apoptotic mechanisms of the human normal glia cell line (HNA), human glioma cell lines (T-98G and U-87MG), and a rat glioma cell line (C6). We also compared the results with the effects of C2 ceramide and cisplatin. We determined the in vitro survival rate with MTT assay, apoptosis with flow cytometry, gene expressions with qRT-PCR, and statistical significance by one-way analysis of variance together with Tukey's test. Calculated from MTT outcomes, the inhibitory ranking was as follows: T-98G > U-87MG > C6 > HNA. Ceranib-2 had the most growth-suppressive activity on human T-98G cells with an IC50 of 7 µM for 24 h and 0.9 µM for 48 h. Only the 25 µM dose of ceranib-2 induced apoptosis of human T-98G and U-87MG cells after 24 h of treatment; however, it increased apoptosis of C6 cells dose- and time-dependently. Ceranib-2 increased the cytochrome c gene expression level during 24 h in T-98G cells. Ceranib-2 had cytotoxic and apoptotic effects on glioma cells but the cytotoxic effect was weaker on normal glia cells. This cytotoxicity was stronger than that of C2 ceramide and cisplatin.

RESUMEN

Cyclophosphamide (CP) is an antineoplastic drug that induces kidney damage via producing oxidative stress. Carvacrol (CAR) has antioxidative effect and we postulated that it can be protective against CP-induced nephrotoxicity. Six groups (n = 7) of rats (control, 100 mg/kg CP, CP+5 mg/kg CAR, CP+10 mg/kg CAR, 5 mg/kg CAR, and 10 mg/kg CAR) were injected intraperitoneally. Serum malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), creatinine (CRE), total antioxidant capacity (TAC), and total oxidant state (TOS) were measured, and oxidative stress indexes (OSI) were calculated. Kidneys were also analyzed histologically. In CP-alone group MDA, CRE, TOS, and OSI levels increased whereas GSH, SOD, CAT, and TAC levels decreased compared with control group. In CP plus CAR groups, MDA, TOS, and OSI levels decreased whereas GSH, SOD, CAT, and TAC levels increased compared with CP-alone group. However, CRE levels were similar in CP-alone and CP+5 CAR group whereas decreased in CP+10 CAR group. CP+10 CAR group was significantly different in all parameters (except TAC) from CP+5 CAR group. Kidney microscopy was showed lower tissue damage in CP plus CAR groups. In conclusion, 10 mg/kg CAR is more effective than 5 mg/kg CAR in prevention of CP-induced oxidative damage on kidney.

Asunto(s)

Antioxidantes/farmacología , Ciclofosfamida/efectos adversos , Riñón/efectos de los fármacos , Riñón/metabolismo , Monoterpenos/farmacología , Estrés Oxidativo/efectos de los fármacos , Animales , Biomarcadores/metabolismo , Catalasa/metabolismo , Creatinina/metabolismo , Cimenos , Relación Dosis-Respuesta a Droga , Glutatión/metabolismo , Masculino , Malondialdehído/metabolismo , Ratas , Ratas Sprague-Dawley , Superóxido Dismutasa/metabolismo

RESUMEN

Ceramidases are key enzymes that decrease ceramide levels in cells. A reduction in ceramide concentration impairs ceramide signalling, and results in apoptosis resistance in cancer cells. This study investigates the potential for ceranib-2, a novel ceramidase inhibitor, to affect the survival and/or promote apoptosis of prostate cancer cells (LNCaP and DU145) in vitro. Cell viability was determined using MTT, and apoptosis assessed via flow cytometry. We examined structural changes with both confocal and transmission electron microscopes. Ceranib-2 concentrations of 0.1, 1, 5, 10, 25 and 50 µM were applied to LNCaP and DU145 cell lines. The corresponding reduction in LNCaP cell viability (against the control) was 84%, 80%, 64%, 56%, 40% and 15% after 24 h, and 81%, 74%, 60%, 55%, 27% and 11% after 48 h. For DU145 cells, viability was reduced to 84%, 82%, 63%, 50%, 41% and 18% after 24 h, and 64%, 42%, 30%, 20%, 8% and 5% after 48 h. Following treatment with 25 and 50 µM ceranib-2, the respective observed rates of early apoptosis in LNCaP cells were 23% and 36% after 24 h and 27% and 58% after 48 h. The morphological and ultrastructural signs of apoptosis detected were fragmented nuclei, chromatin condensations and cytoskeleton laceration. The inhibitory effects of ceranib-2 on prostate cancer cell survival are dose and time dependent. For LNCaP cells, ceranib-2 toxicity was predominately apoptotic in nature, while for DU145 cells, cell death may be related to non-apoptotic mechanisms.

Asunto(s)

Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Ceramidasas/antagonistas & inhibidores , Neoplasias de la Próstata/tratamiento farmacológico , Quinolonas/farmacología , Línea Celular Tumoral , Humanos , Masculino , Microscopía Confocal , Microscopía Electrónica de Transmisión , Próstata/citología , Próstata/patología

RESUMEN

Dual inhibitors of cyclooxygenase (COX) and lipoxygenase (LOX) pathways of arachidonic acid metabolism prevent cancer development and induce apoptosis. One of the most promising compounds that blocks both of these pathways is licofelone. We questioned whether licofelone affects the survival and/or promotes apoptosis of H-ras transformed rat embryonic fibroblast (5RP7) cells in vitro. Using 5-fluorouracil (5-FU) and colchicine as positive controls, we determined cell viability with 3-3-(4,5-D-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, thyazolyl blue (MTT), apoptosis with flow cytometry and activity of caspase enzyme with real-time reverse transcription polymerase chain reaction (PCR). Compared to the control, all used six doses (10, 50, 100, 150, 250 and 250 µM) of 5-FU, colchicine and licofelone, which were cytotoxic and reduced the number of H-Ras transformed 5RP7 cells by as much as 78, 72 and 92%, respectively. In addition, we found that 150, 200 and 250 µM of licofelone induced apoptosis and necrosis of H-Ras transformed 5RP7 cells in a dose- and time-dependent manner. Each three tested drugs at 250 µM also increased the level of caspase-3 enzyme up to 5-fold. Although colchicine was effective in inducing early apoptosis, licofelone had much more capacity to induce the total of early plus late apoptosis by approximately 96% in cells after 48 hours. The present study reveals the possibility that licofelone posseses strong dose- and time-dependent anticancer and apoptotic properties on carcinogenic fibroblasts.

Asunto(s)

Apoptosis/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Pirroles/farmacología , Análisis de Varianza , Animales , Transformación Celular Neoplásica/genética , Cartilla de ADN/genética , Relación Dosis-Respuesta a Droga , Embrión de Mamíferos/citología , Citometría de Flujo , Fluorouracilo , Ratas , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Sales de Tetrazolio , Tiazoles , Factores de Tiempo , Azul de Tripano , Células Tumorales Cultivadas/efectos de los fármacos

RESUMEN

Gliomas are the largest group of central nervous system tumors and despite of clinical treatments death rate is very high. Inhibition of both cyclooxygenase and lipoxygenase pathways that take role in arachidonic acid metabolism prevents cancer development and induces apoptosis. One of the most promising compounds that blocks both of these pathways is licofelone. Using colchicine and 5-fluorouracil as positive controls, we questioned whether licofelone affects the survival of rat glioma cell line (C6) and induces apoptosis in vitro. After growing the cells in culture, we determined viability with MT, apoptosis with flow cytometry and activity of caspase enzymes with real time PCR. All used doses of colchicine and 5-fluorouracil were cytotoxic and reduced the number of surviving C6 cells as much as 44% and 60%, respectively. Comparing to the control, treatments with 10, 50 and 100 µM licofelone for 24 or 48 h did not influence C6 survival, however, 150, 200 and 250 µM licofelone reduced the number of living cells by 58, 88 and 93%, respectively, and induced apoptosis of C6 cells in a dose and time dependent manner. Licofelone did not change the level of caspase-9, but increased the level of caspase-3. Comparing with 5-fluorouracil and colchicine, the present study reveals for the first time the possibility that licofelone possesses a strong dose and time dependent antiproliferative and proapoptotic properties on glioma cells.

Asunto(s)

Glioma/tratamiento farmacológico , Pirroles/uso terapéutico , Animales , Apoptosis/efectos de los fármacos , Caspasa 3/metabolismo , Caspasa 9/metabolismo , Línea Celular Tumoral , Ensayos de Selección de Medicamentos Antitumorales , Citometría de Flujo , Glioma/enzimología , Pirroles/farmacología , Ratas

RESUMEN

In this study, four mononuclear M(II)-pyridine-2,5-dicarboxylate (M = Co(II), Ni(II), Cu(II) and Zn(II) complexes with pyridine-2,5-dicarboxylic acid or isocinchomeronic acid, 1,10-phenanthroline (phen), [Co(Hpydc)(2)(phen)]·H(2)O (1), [Ni(pydc)(phen)(2)]·6.5H(2)O (2) [Cu(pydc)(phen)(H(2)O)(2)] (3) and [Zn(pydc)(phen)(H(2)O)(2)]·H(2)O (4) have been synthesized. Elemental, thermal and mass analyses, molar conductance, magnetic susceptibilities, IR and UV/vis spectroscopic studies have been performed to characterize the complexes. Subsequently, these ligands and complexes were tested for antimicrobial activity by disc diffusion method on Gram positive, negative bacteria and yeast. In addition, cytotoxic activity tests were performed on rat glioma (C6) cells by MTT viability assay for 24 and 48 h. Antimicrobial activity results demonstrated that when compared to the standard antibiotics, phen displayed the most effective antimicrobial effect. The effect of synthesized complexes was close to phen or less. Cytotoxic activity results showed that IC(50) value of phen was determined as 31 µM for 48 h. (1) and (2) compared to the alone ligand had less toxic activity. IC(50) values of (3) for 24 and 48 h treatments were 2.5 and 0.6 µM, respectively. IC(50) value of (4) for 48 h was 15 µM. In conclusion, phen, (3) and (4) may be useful as antibacterial and antiproliferative agents in the future.

Asunto(s)

Antibacterianos/farmacología , Antifúngicos/farmacología , Antineoplásicos/farmacología , Neoplasias del Sistema Nervioso Central/tratamiento farmacológico , Glioma/tratamiento farmacológico , Compuestos Organometálicos/farmacología , Animales , Antibacterianos/síntesis química , Antibacterianos/química , Antifúngicos/síntesis química , Antifúngicos/química , Antineoplásicos/síntesis química , Antineoplásicos/química , Bacterias/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Neoplasias del Sistema Nervioso Central/patología , Cobalto/química , Cobre/química , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Glioma/patología , Estructura Molecular , Níquel/química , Compuestos Organometálicos/síntesis química , Compuestos Organometálicos/química , Fenantrolinas/química , Piridinas/química , Ratas , Saccharomyces cerevisiae/efectos de los fármacos , Relación Estructura-Actividad , Zinc/química

RESUMEN

The anticancer drug cyclophosphamide (CP) has nephrotoxic effects besides its urotoxicity, which both in turn limit its clinical utility. The nephrotoxicity of CP is less common compared to its urotoxicity, and not much importance has been given for the study of mechanism of CP-induced nephrotoxicity so far. Overproduction of reactive oxygen species (ROS) during inflammation is one of the reasons of the kidney injury. Selenoproteins play crucial roles in regulating ROS and redox status in nearly all tissues; therefore, in this study, the nephrotoxicity of CP and the possible protective effects of seleno L-methionine (SLM) on rat kidneys were investigated. Forty-two Sprague-Dawley rats were equally divided into six groups of seven rats each. The control group received saline, and other rats were injected with CP (100 mg/kg), SLM (0.5 or 1 mg/kg), or CP + SLM intraperitoneally. Malondialdehyde (MDA) and glutathione (GSH) levels in kidney homogenates of rats were measured, and kidney tissues were examined under the microscope. CP-treated rats showed a depletion of renal GSH levels (28% of control), while CP + SLM-injected rats had GSH values close to the control group. MDA levels increased 36% of control following CP administration, which were significantly decreased after SLM treatment. Furthermore, these biochemical results were supported by microscopical observations. In conclusion, the present study not only points to the therapeutic potential of SLM in CP-induced kidney toxicity but also indicates a significant role for ROS and their relation to kidney dysfunction.

Asunto(s)

Antineoplásicos/toxicidad , Antioxidantes/farmacología , Ciclofosfamida/toxicidad , Riñón/efectos de los fármacos , Selenometionina/farmacología , Animales , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Ciclofosfamida/efectos adversos , Ciclofosfamida/uso terapéutico , Femenino , Glutatión/sangre , Riñón/patología , Masculino , Malondialdehído/sangre , Ratas , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/toxicidad , Estándares de Referencia

RESUMEN

Cyclophosphamide (CP) is a widely used antineoplastic drug, which could cause toxicity of the normal cells due to its toxic metabolites. Its urotoxicity may cause dose-limiting side effects like hemorrhagic cystitis. Overproduction of reactive oxygen species (ROS) during inflammation is one of the reasons of the urothelial injury. Selenoproteins play crucial roles in regulating ROS and redox status in nearly all tissues; therefore, in this study, the urotoxicity of CP and the possible protective effects of seleno-L: -methionine (SLM) on urinary bladder of rats were investigated. Intraperitoneal (i.p.) administration of 50, 100, or 150 mg/kg CP induced cystitis, in a dose-dependent manner, as manifested by marked congestion, edema and extravasation in rat urinary bladder, a marked desquamative damage to the urothelium, severe inflammation in the lamina propria, focal erosions, and polymorphonuclear (PMN) leukocytes associated with occasional lymphocyte infiltration determined by macroscopic and histopathological examination. In rat urinary bladder tissue, a significant decrease in the endogenous antioxidant compound glutathione, and elevation of lipid peroxidation were also noted. Pretreatment with SLM (0.5 or 1 mg/kg) produced a significant decrease in the bladder edema and caused a marked decrease in vascular congestion and hemorrhage and a profound improvement in the histological structure. Moreover, SLM pretreatment decreased lipid peroxide significantly in urinary bladder tissue, and glutathione content was greatly restored. These results suggest that SLM offers protective effects against CP-induced urinary bladder toxicity and could be used as a protective agent against the drug toxicity.

Asunto(s)

Antineoplásicos Alquilantes/toxicidad , Ciclofosfamida/toxicidad , Selenometionina/farmacología , Vejiga Urinaria/efectos de los fármacos , Animales , Femenino , Humanos , Masculino , Oxidación-Reducción , Distribución Aleatoria , Ratas , Especies Reactivas de Oxígeno/metabolismo , Vejiga Urinaria/citología , Vejiga Urinaria/metabolismo , Vejiga Urinaria/patología

RESUMEN

Neurons and glia are highly susceptible to reactive oxygen species that play a key role in various neurodegenerative diseases. Menadione, a synthetic derivative of vitamin K, induces reactive oxygen generation. Quercetin one of the most ubiquitous bioflavonoids in food of plant origin, has strong antioxidant activities on different cell types, however recent studies demonstrated that it has also prooxidant and cytotoxic potentials. We examined the action of pre- and co-treatment of quercetin on menadione induced glial toxicity. The primary mixed glial cells obtained from 1 to 3 day old rat brain were pretreated with 10, 25, 100 or 250 muM quercetin for 1 h, washed out and 10, 25, 50, 75 or 100 muM menadione was added for 6 h. The other group of cells was treated with respective doses of quercetin combined simultaneously with the same doses of menadione for 6 h. The cells were washed and incubated for additional 24 h for recovery period and the viability was measured by using MTT assay. Menadione was dose-dependently toxic to glia cells and pretreatment with respective quercetin doses for 1 h could not eliminate this toxicity. Although 10 and 25 muM quercetin combined with 10 and 25 muM menadione could not change, 100 and 250 muM quercetin together with 10 or 25 muM menadione for 6 h increased further the menadione induced toxicity. We conclude that when combined with menadione, quercetin at high doses could be toxic to primary rat glia cells in culture.

RESUMEN

Cyclophosphamide (CP) is widely used for the treatment of neoplastic diseases; however, its toxicity causes dose-limiting side effects. Zinc (Zn) is an essential trace element and has important biological functions that control many cell processes including DNA synthesis, normal growth, reproduction, fetal development, bone formation, and wound healing. Therefore, the toxicity of CP and the possible protective effect of Zn on blood cells, bone marrow, and bladder of rat were investigated in this study. Intraperitoneal administration of 50, 100, or 150 mg/kg CP for 3 days caused, in a dose-dependent manner, reductions in the number of leukocytes, thrombocytes, and bone marrow nucleated cells and a serious urotoxicity. To explore whether CP-induced damages could be prevented by Zn, other groups of rats were pretreated with 4 or 8 mg/kg ZnCl2 intraperitoneally for 3 days then challenged with respective doses of CP plus ZnCl2 on day 4 for three more days. The results indicated that treatment of rats with Zn could dose-dependently alleviate CP-induced toxicities on blood cells, bone marrow cells, and urinary bladder. We suggest that Zn could be a potentially effective drug in the prevention of CP-related hematoxicity and urotoxicity.

Asunto(s)

Plaquetas/efectos de los fármacos , Células de la Médula Ósea/efectos de los fármacos , Ciclofosfamida/efectos adversos , Leucocitos/efectos de los fármacos , Zinc/farmacología , Animales , Plaquetas/citología , Células de la Médula Ósea/citología , Femenino , Inyecciones Intraperitoneales , Leucocitos/citología , Masculino , Ratas , Ratas Sprague-Dawley , Vejiga Urinaria/efectos de los fármacos , Zinc/administración & dosificación

RESUMEN

There is enough evidence that erythropoietin (EPO) may be involved in cardiovascular function. Therefore we have investigated the possible effects of EPO on left ventricular developed pressure, +dP/dt(max), heart rate, tissue cAMP, and nitrite levels. Isolated rat hearts were perfused under constant flow (10 ml/min) conditions with modified Krebs-Henseleit solution and recombinant human erythropoietin at doses of 100, 200, 500, and 1,000 IU/kg was administered as bolus injections. EPO at 100 IU/kg decreased, but higher doses (500 and 1,000 IU/kg) raised the developed pressure and +dP/dt(max). However, it did not affect heart rate or coronary perfusion pressure when all the respective doses were applied. EPO at 100 IU/kg increased nitrite, and at 1,000 IU/kg it raised cAMP. Our results suggest that EPO may produce dose-dependently negative and positive inotropic effects on myocardial contractility in isolated rat hearts. NO and cAMP may be involved in negative and positive inotropic effects of EPO, respectively.

Asunto(s)

AMP Cíclico/metabolismo , Eritropoyetina/fisiología , Contracción Miocárdica/fisiología , Miocardio/metabolismo , Nitritos/metabolismo , Animales , Relación Dosis-Respuesta a Droga , Femenino , Corazón/fisiología , Frecuencia Cardíaca/fisiología , Masculino , Ratas , Ratas Sprague-Dawley , Volumen Sistólico/fisiología , Factores de Tiempo

RESUMEN

Leptin, a circulating hormone mainly produced by adipose tissue, regulates fatty acid metabolism and causes multiple systemic biological actions even the regulation of cardiovascular function. It is previously known that leptin is a hypoxia-inducible hormone, that hypoxic conditions increase the expression of this peptide in various tissues such as placenta, pancreas and also in the heart. Since leptin receptors are present in the heart, we hypothesized that whether leptin was a protector response for tissues especially for the heart against the deleterious effects of hypoxia. Cultured cardiomyocytes from newborn rats were initially treated with 3000 ng/ml leptin incubation for 1, 5 and 20 h separately, then subjected to 120 min of hypoxia. Hypoxic damage of myocytes was assayed using the measurements of both lactate dehydrogenase and creatine kinase releases into the medium and performing morphological observations (ultrastructural and immunocytochemical) of plates. The obtained results from leptin treated and non-treated control groups were compared to each other, and these data have demonstrated that 5 h of leptin treatment before hypoxia provides a significant protection for cardiomyocytes against hypoxia. Neither 1- nor 20-h leptin treated groups exhibited sufficient protection against hypoxia. In conclusion, leptin protects the cardiomyocyte cultures from hypoxia, but this effect is selective and evident only in the 5-h treated myocytes.

Asunto(s)

Hipoxia de la Célula/efectos de los fármacos , Hipoxia de la Célula/fisiología , Leptina/farmacología , Miocitos Cardíacos/efectos de los fármacos , Animales , Células Cultivadas , Creatina Quinasa/sangre , Medios de Cultivo , Desmina/farmacología , Inmunohistoquímica , L-Lactato Deshidrogenasa/sangre , Miocitos Cardíacos/enzimología , Miocitos Cardíacos/ultraestructura , Ratas

RESUMEN

In this study, the possible effects of MgSO4 and lazaroid (U-83836E) on glutamate toxicity on glial cells were investigated. C6 and human glioblastoma multiforme cells derived from two patients were grown in an incubator. First, determined IC50 dose of L-glutamate (L-glu) was given for 24 hours and removed, and then respective MgSO4 or U-83836E doses were added to the culture medium. After 24 hours 3-(4,5-Dimethylthyazol-2-yl)-2,5-diphenyltetrazolium bromide, thiazolyl blue (MTT) test was applied. When compared to the L-glu-treated group, MgSO4 at the dose of 0.01 mM induced C6 and human glioma cell growth by 17%, 15% and 5%, respectively. At the dose of 1 microM U-83836E also increased C6 and human glioma cell growth by 12%, 13% and 5%, respectively. In conclusion, although MgSO4 and U-83836E do not strongly block glutamate-induced cell death, it is suggested that reduction of Mg2+ ions and free radical production may have a role in glutamate toxicity on glial cells.

Asunto(s)

Antioxidantes/farmacología , Bloqueadores de los Canales de Calcio/farmacología , Cromanos/farmacología , Ácido Glutámico/farmacología , Sulfato de Magnesio/farmacología , Neuroglía/efectos de los fármacos , Piperazinas/farmacología , Animales , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Glioma , Humanos , Concentración 50 Inhibidora , Ratones , Neuroglía/citología , Sales de Tetrazolio , Tiazoles

RESUMEN

Glioblastoma multiforme is characterized as highly invasive and rapidly growing astrocytomas, and scientists have sought for efficient treatment against malignant gliomas for a long time. Therefore, we compared the respond of rat glioma (C6) and glioblastoma multiforme cells derived from two patients to vitamins K1, K2 and K3. The cells were exposed to 100, 250, 500, 750 and 1000 microM of vitamins K1 and K2, and 1, 10, 25, 50, 75 and 100 microM of vitamin K3 for 24 hours in an incubator atmosphere of 5% CO2, 37 degrees C and 100% humidity. Cell viability was estimated by MTT assay. Vitamin K1 showed no growth effect on all the glioma cells examined. Vitamin K2 did not cause any change in number of C6, however induced growth inhibition in a dose-dependent manner on glioblastoma multiforme. The IC50 values of vitamin K2 were 960 microM and 970 microM for glioblastoma multiforme, respectively. Vitamin K3 had also growth inhibitory effect in a dose-dependent manner on both C6 and glioblastoma multiforme. The IC50 values were 41 microM, 24 microM and 23 microM for vitamin K3, respectively. We concluded that vitamin K3 is more effective than vitamin K2 for inhibition of cancer cell growth, and might have an alternative value as an anticancer drug against glioblastoma multiforme.

Asunto(s)

Glioblastoma/tratamiento farmacológico , Glioma/tratamiento farmacológico , Vitamina K 1/uso terapéutico , Vitamina K 2/uso terapéutico , Vitamina K 3/uso terapéutico , Animales , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Glioblastoma/patología , Glioma/patología , Humanos , Ratas , Células Tumorales Cultivadas , Vitamina K 1/farmacología , Vitamina K 2/farmacología , Vitamina K 3/farmacología

RESUMEN

The antitumoral activity of nonsteroidal antiestrogens on C6 and low passage of human glioma cells was investigated. Tamoxifen and its metabolite, 4-hydroxytamoxifen, did not influence viability of the human cells, but tamoxifen had a limited antiproliferative effect on C6 cells (IC50: 49 micromol/l). The derivatives of tamoxifen, nafoxidine and clomiphene, caused reduction of living cell number in a dose-dependent manner. These two drugs showed differences in their potency following 24-hour incubation in a humidified atmosphere with 37 degrees C and 5% CO2. Obtained from a tetrazolium-formazan growth rate assay, IC50 of nafoxidine for C6 cells was calculated as 44 micromol/l and for the human cells as 16.5 micromol/l. The calculated IC50 dose of clomiphene for C6 is 16 micromol/l and for the human cells 13 micromol/l. Compared to the other drugs we used, it is clear that clomiphene is the most efficient inhibitor of C6 and the human glioma cells. These preliminary results suggest that nafoxidine and clomiphene possess antiproliferative effect on two different sources of glioma cells and therefore, instead of tamoxifen, multiple activities of these drugs may enable their use in combination therapy of glioblastoma malignancies.

Asunto(s)

Antineoplásicos Hormonales/farmacología , División Celular/efectos de los fármacos , Clomifeno/farmacología , Antagonistas de Estrógenos/farmacología , Glioma/tratamiento farmacológico , Nafoxidina/farmacología , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Ratas , Tamoxifeno/farmacología , Ensayo de Tumor de Célula Madre